Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12712474 | 0.81 | HRH3 (0.53) | HRH3CYP1A2CYP2D6PPARGCYP3A4 | |
| SCHEMBL10090163 | 0.81 | HRH3 (0.53) | HRH3CYP1A2CYP2D6PPARGCYP3A4 | |
| SCHEMBL2608894 | 0.81 | HRH3 (0.47) | HRH3CYP1A2CYP2D6PPARGCYP3A4 | |
| SCHEMBL6920660 | 0.79 | PDE10A (0.38) | PPARGKDM4E | |
| SCHEMBL2614817 | 0.79 | HRH3 (0.51) | HRH3CYP1A2CYP2D6PPARGCYP3A4 | |
| SCHEMBL26329124 | 0.78 | HRH3 (0.50) | HRH3CYP1A2CYP2D6PPARGCYP3A4 | |
| SCHEMBL19313384 | 0.78 | DEGS1 (0.31) | PPARG | |
| SCHEMBL2619346 | 0.76 | HRH3 (0.59) | HRH3CYP1A2CYP2D6PPARGCYP3A4 | |
| SCHEMBL16886090 | 0.76 | HRH3 (0.37) | HRH3CYP1A2CYP2D6PPARGRXRA | |
| SCHEMBL4325068 | 0.75 | PPARG (0.55) | HRH3CYP1A2CYP2D6PPARGCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767317-B1 | Methods of synthesizing enantiopure deuterium-enriched pioglitazone | POXEL SA (FR) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767317-B1 | Methods of synthesizing enantiopure deuterium-enriched pioglitazone | PPARD, GLP1R, DPP4 | HRH3 2524/4885CYP1A2 421/4885CYP2D6 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.